CoChat

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 14 of the 27 sources its claims cite were checked for support.

Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study

Open access

Abstract

Carbohydrate restriction markedly improves glycemic control in patients with type 2 diabetes (T2D) but necessitates prompt medication changes. Therefore, we assessed the effectiveness and safety of a novel care model providing continuous remote care with medication management based on biometric feedback combined with the metabolic approach of nutritional ketosis for T2D management. We conducted an open-label, non-randomized, controlled, before-and-after 1-year study of this continuous care intervention (CCI) and usual care (UC). Primary outcomes were glycosylated hemoglobin (HbA1c), weight, and medication use. Secondary outcomes included fasting serum glucose and insulin, HOMA-IR, blood lipids and lipoproteins, liver and kidney function markers, and high-sensitivity C-reactive protein (hsCRP). 349 adults with T2D enrolled: CCI: n = 262 [mean (SD); 54 (8) years, 116.5 (25.9) kg, 40.4 (8.8) kg m2, 92% obese, 88% prescribed T2D medication]; UC: n = 87 (52 (10) years, 105.6 (22.15) kg, 36.72 (7.26) kg m2, 82% obese, 87% prescribed T2D medication]. 218 participants (83%) remained enrolled in the CCI at 1 year. Intention-to-treat analysis of the CCI (mean ± SE) revealed HbA1c declined from 59.6 ± 1.0 to 45.2 ± 0.8 mmol mol−1 (7.6 ± 0.09% to 6.3 ± 0.07%, P < 1.0 × 10−16), weight declined 13.8 ± 0.71 kg (P < 1.0 × 10−16), and T2D medication prescription other than metformin declined from 56.9 ± 3.1% to 29.7 ± 3.0% (P < 1.0 × 10−16). Insulin therapy was reduced or eliminated in 94% of users; sulfonylureas were entirely eliminated in the CCI. No adverse events were attributed to the CCI. Additional CCI 1-year effects were HOMA-IR − 55% (P = 3.2 × 10−5), hsCRP − 39% (P < 1.0 × 10−16), triglycerides − 24% (P < 1.0 × 10−16), HDL-cholesterol + 18% (P < 1.0 × 10−16), and LDL-cholesterol + 10% (P = 5.1 × 10−5); serum creatinine and liver enzymes (ALT, AST, and ALP) declined (P ≤ 0.0001), and apolipoprotein B was unchanged (P = 0.37). UC participants had no significant changes in biomarkers or T2D medication prescription at 1 year. These results demonstrate that a novel metabolic and continuous remote care model can support adults with T2D to safely improve HbA1c, weight, and other biomarkers while reducing diabetes medication use. NCT02519309. Virta Health Corp. Treatments for type 2 diabetes (T2D) have improved, yet T2D and being overweight are still significant public health concerns. Blood sugar in patients with T2D can improve quickly when patients eat significantly fewer dietary carbohydrates. However, this demands careful medicine management by doctors, and patients need support and frequent contact with health providers to sustain this way of living. The purpose of this study was to evaluate if a new care model with very low dietary carbohydrate intake and continuous supervision by a health coach and doctor could safely lower HbA1c, weight and need for medicines after 1 year in adults with T2D. 262 adults with T2D volunteered to participate in this continuous care intervention (CCI) along with 87 adults with T2D receiving usual care (UC) from their doctors and diabetes education program. After 1 year, patients in the CCI, on average, lowered HbA1c from 7.6 to 6.3%, lost 12% of their body weight, and reduced diabetes medicine use. 94% of patients who were prescribed insulin reduced or stopped their insulin use, and sulfonylureas were eliminated in all patients. Participants in the UC group had no changes to HbA1c, weight or diabetes medicine use over the year. These changes in CCI participants happened safely while dyslipidemia and markers of inflammation and liver function improved. This suggests the novel care model studied here using dietary carbohydrate restriction and continuous remote care can safely support adults with T2D to lower HbA1c, weight, and medicine use.

Overview

CoChat Summary

TL;DR

In an open-label, non-randomized, controlled 1-year study, a continuous care intervention combining remote care with nutritional ketosis was associated with improved HbA1c, weight, and medication use in adults with type 2 diabetes, while usual care showed no significant biomarker changes. No adverse events were attributed to the intervention.

Key findings

  • Among 349 enrolled adults (CCI n = 262; UC n = 87), 218 CCI participants (83%) remained enrolled at 1 year. Intention-to-treat CCI results showed HbA1c declined from 59.6 ± 1.0 to 45.2 ± 0.8 mmol/mol (7.6 ± 0.09% to 6.3 ± 0.07%, P < 1.0 × 10−16), weight declined 13.8 ± 0.71 kg (P < 1.0 × 10−16), and diabetes medication prescription other than metformin declined from 56.9 ± 3.1% to 29.7 ± 3.0% (P < 1.0 × 10−16).
  • Insulin therapy was reduced or eliminated in 94% of users, and sulfonylureas were entirely eliminated in the CCI; UC participants had no significant changes in biomarkers or T2D medication prescription at 1 year.
  • Additional CCI 1-year effects included HOMA-IR −55% (P = 3.2 × 10−5), hsCRP −39% (P < 1.0 × 10−16), triglycerides −24% (P < 1.0 × 10−16), HDL-cholesterol +18% (P < 1.0 × 10−16), and LDL-cholesterol +10% (P = 5.1 × 10−5); apolipoprotein B was unchanged (P = 0.37).
  • No adverse events were attributed to the CCI; no cases of metabolic acidosis were observed, and one CCI patient (0.38% of starters) had a clinically significant rise in serum creatinine.

Methods

  • Open-label, non-randomized, controlled, before-and-after 1-year study of a continuous care intervention (CCI) versus usual care (UC) in adults with T2D, recruited in Lafayette, Indiana, USA, from August 2015 through March 2016 (NCT02519309).
  • CCI included remote care, telemedicine, health coaching, biometric feedback, and individualized nutrition targeting nutritional ketosis (goal blood BHB 0.5–3.0 mmol/L); UC participants received their own medical care and diabetes education.
  • Primary outcomes were HbA1c, weight, and medication use; secondary outcomes included fasting glucose and insulin, HOMA-IR, lipids, liver and kidney markers, and hsCRP. Analyses used intention-to-treat with multiple imputation (700 imputations), completer analyses, and adjustment for baseline covariates.

Limitations

  • Stated by the paper: the study occurred at a single site, participants were mostly Caucasian, socioeconomic and psychosocial status and genetics data were not collected, and the study was not of sufficient size or duration to measure hard endpoints such as mortality.
  • Evident from the text: the non-randomized design allowed self-selection into CCI versus UC, and the authors note possible differences in motivation, expectations, and treatment intensity between groups.
  • Evident from the text: 24% of 1-year biomarker values were missing and imputed, and the CCI and UC groups differed at baseline on some characteristics, although analyses adjusted for sex, age, baseline BMI, insulin use, and African-American race.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s13300-018-0373-9

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Change in HbA1c over the course of 1 year for CCI and UC groups. a Mean (95% CI) in HbA1c based on starting value at baseline and 1 year for completers in both groups. b Individual changes in HbA1c over 1 year for completers in both groups
Fig. 1 Change in HbA1c over the course of 1 year for CCI and UC groups. a Mean (95% CI) in HbA1c based on starting value at baseline and 1 year for completers in both groups. b Individual changes in HbA1c over 1 year for completers in both groupsCC BY · PubMed Central
Fig. 2 Body weight change over the course of 1 year in CCI completers. a Mean (95% CI) change in body weight for completers over the course of 1 year. For each individual, weight on a given day was computed as the 3-day trailing mean (to reduce day-to-day variation). On dates where no weights were recorded during the 3-day time window for a given participant, the most recent 3-day mean preceding the date was used. b Histogram depicting individual body weight changes at 1 year
Fig. 2 Body weight change over the course of 1 year in CCI completers. a Mean (95% CI) change in body weight for completers over the course of 1 year. For each individual, weight on a given day was computed as the 3-day trailing mean (to reduce day-to-day variation). On dates where no weights were recorded during the 3-day time window for a given participant, the most recent 3-day mean preceding the date was used. b Histogram depicting individual body weight changes at 1 yearCC BY · PubMed Central
Fig. 3 Medication changes over the course of 1 year in completers of the CCI and UC groups. a Proportion of completers prescribed diabetes medications other than metformin. b Mean ± SE prescribed dose among insulin users. c Frequency in change of medication dosage among prescribed users by diabetes medication class in both groups
Fig. 3 Medication changes over the course of 1 year in completers of the CCI and UC groups. a Proportion of completers prescribed diabetes medications other than metformin. b Mean ± SE prescribed dose among insulin users. c Frequency in change of medication dosage among prescribed users by diabetes medication class in both groupsCC BY · PubMed Central
Fig. 4 Beta-hydroxybutyrate concentrations of CCI completers. Note: For each individual in the graph, the BHB concentration on a given day was computed as the 3-day trailing mean (to reduce day-to-day variation). On dates where no BHB concentrations were recorded during the 3-day time window for a given participant, the most recent 3-day mean preceding the date was used. Line graph depicts mean (95% CI) over time for BHB measured at home and reported via the app. Dots and error bars represent the mean ± SE from laboratory measured BHB at baseline, 70 days, and 1 year
Fig. 4 Beta-hydroxybutyrate concentrations of CCI completers. Note: For each individual in the graph, the BHB concentration on a given day was computed as the 3-day trailing mean (to reduce day-to-day variation). On dates where no BHB concentrations were recorded during the 3-day time window for a given participant, the most recent 3-day mean preceding the date was used. Line graph depicts mean (95% CI) over time for BHB measured at home and reported via the app. Dots and error bars represent the mean ± SE from laboratory measured BHB at baseline, 70 days, and 1 yearCC BY · PubMed Central

Verification

Claims the paper makes

9 Valid · 0 Not valid · 8 Not checked · 116 Own results and interpretations

78 more claims

Create a free account to see all 133 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 37
  • Probably not a substantial claim. 21

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

11 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 54 references

Cited by

See all 407

Metadata

Authors
Hallberg, S. J., McKenzie, A. L., Williams, P. T., Bhanpuri, N. H., Peters, A. L., Campbell, W. W., Hazbun, T. L., Volk, B. M., McCarter, J. P., Phinney, S. D., & Volek, J. S.
Affiliations
  • Indiana University Health (US)
  • University of Southern California (US)
  • Purdue University West Lafayette (US)
  • Washington University in St. Louis (US)
  • The Ohio State University (US)
Corresponding author
McKenzie, Amy L.
Venue
Diabetes Therapy
Published
2018-02-07
Volume
9
Issue
2
Pages
583-612
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W2785914398
Cited by
406
References
54
Citations by year
2026: 40 · 2025: 40 · 2024: 51 · 2023: 40 · 2022: 45 · 2021: 67 · 2020: 50 · 2019: 48 · 2018: 25
FWCI
37.81
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Virta Health
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
type 2 diabetes, remote care, biometric feedback, nutritional ketosis, carbohydrate restriction, glycemic control, HbA1c, weight loss, medication management, HOMA-IR, insulin resistance, serum lipids, C-reactive protein, liver and kidney function, obesity, diabetes care model

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study. https://app.cochat.ai/papers/10.1007/s13300-018-0373-9
The paper
Hallberg, S. J., McKenzie, A. L., Williams, P. T., Bhanpuri, N. H., Peters, A. L., Campbell, W. W., Hazbun, T. L., Volk, B. M., McCarter, J. P., Phinney, S. D., & Volek, J. S. (2018). Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study. Diabetes Therapy. https://doi.org/10.1007/s13300-018-0373-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.